Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 18, 2016

Catalyst begins enrolment for second Phase III LMS-003 trial of Firdapse to treat LEMS

US-based biopharmaceutical company Catalyst has begun enrolment for its second Phase III LMS-003 clinical trial of Firdapse to treat Lambert-Eaton myasthenic syndrome (LEMS).

US-based biopharmaceutical company Catalyst has begun enrolment for its second Phase III LMS-003 clinical trial of Firdapse to treat Lambert-Eaton myasthenic syndrome (LEMS).

Firdapse is amifampridine phosphate or 3,4-diaminopyridine phosphate (3,4-DAP) that has obtained an orphan drug designation in the US and orphan medicinal product designation in the European Union to treat LEMS.

LEMS is an autoimmune neuromuscular disease resulting in a decrease of the release of acetylcholine at the neuromuscular junction, triggering muscle weakness.

Firdapse acts by increasing acetylcholine release, thereby addressing muscle weakness caused by the disease.

The second Phase III, double-blind, placebo-controlled withdrawal LMS-003 trial will be conducted across clinical trial sites in the US.

"The initiation of our second Phase III study of Firdapse in LEMS patients is a significant step forward on our path towards gaining approval for Firdapse."

The trial will test the safety and efficacy of Firdapse while treating approximately 28 subjects with LEMS.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

It will share the same co-primary endpoints with the first Phase III trial, which tested Firdapse for the treatment of LEMS.

Catalyst CEO Patrick McEnany said: "The initiation of our second Phase III study of Firdapse in LEMS patients is a significant step forward on our path towards gaining approval for Firdapse.

"We believe we have a clearly defined development and regulatory pathway for Firdapse in the treatment of LEMS and remain focused on our goal of improving access to treatments for patients with this significant unmet need."

Additionally, the US Food and Drug Administration (FDA) has approved Catalyst to include patients from its expanded access programme as study subjects in this second trial.

The company is planning to re-submit a new drug application (NDA) for its product and is expecting the train results in the second half of next year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU